ArticlePediatric nephrology (Berlin, Germany)2026
Improving hemolytic uremic syndrome diagnosis in children: the role of serology for Shiga toxin-producing Escherichia coli detection.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetically negative aHUS and the possibility of undetected STEC-HUS.Pediatric nephrology (Berlin, Germany) · 2026Article
- Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection.Archives of microbiology · 2026Review
- Non-Diarrheal STEC-HUS in Children: Expanding the Clinical and Diagnostic Spectrum.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating STEC-HUS from aHUS can be challenging due to overlapping clinical presentations. Confirming STEC infection is crucial to guide treatment. Although fecal testing is the gold standard, it confirms the diagnosis in only about half of HUS cases. Detection of anti-O-polysaccharide antibodies (anti-LPS) by using Glyco-iELISA can improve the diagnosis rate. The aim of this study was to assess the diagnostic contribution of anti-LPS for STEC confirmation in patients with negative stool results with consideration of sample collection time, the presence/absence of bloody diarrhea, and prior antibiotic use.
methodsA two-center retrospective study was conducted, including 137 patients with STEC-HUS evaluated by both fecal PCR and anti-LPS testing.
resultsSTEC infection was confirmed in 45 (35.2%) patients by stool culture, in 87 (63.5%) by PCR, and in 100 (73%) by anti-LPS. Anti-LPS was positive in 35 patients with negative stool results, increasing the diagnostic rate to 90.5%, with an added diagnostic value of 25.5% (p = 0.0001). Stool STEC detection was significantly lower in patients without bloody diarrhea (p = 0.02), in those who received antibiotics (p = 0.004), and in those whose stool samples were collected ≥ 7 days after symptom onset (p = 0.0002). After multivariate analysis, only the use of antibiotics (p = 0.01) and delayed sample collection (p = 0.002) remained negatively associated with stool STEC detection. In contrast, anti-LPS antibodies' results were unaffected by these variables.
conclusionsSTEC infection was confirmed in 90.5% of children with STEC-HUS. Anti-LPS serology significantly contributed to diagnosis, especially in patients with delayed stool tests and in those treated with antibiotics.
Indexed as
Identifiers
41511556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.